AU2001273499A1 - Combination of 2-methoxyestradiol and an agent that increases intracellular superoxide anion - Google Patents

Combination of 2-methoxyestradiol and an agent that increases intracellular superoxide anion

Info

Publication number
AU2001273499A1
AU2001273499A1 AU2001273499A AU7349901A AU2001273499A1 AU 2001273499 A1 AU2001273499 A1 AU 2001273499A1 AU 2001273499 A AU2001273499 A AU 2001273499A AU 7349901 A AU7349901 A AU 7349901A AU 2001273499 A1 AU2001273499 A1 AU 2001273499A1
Authority
AU
Australia
Prior art keywords
methoxyestradiol
agent
combination
superoxide anion
increases intracellular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001273499A
Inventor
Li Feng
Peng Huang
William K. Plunkett
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Publication of AU2001273499A1 publication Critical patent/AU2001273499A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2001273499A 2000-07-12 2001-07-11 Combination of 2-methoxyestradiol and an agent that increases intracellular superoxide anion Abandoned AU2001273499A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US21758900P 2000-07-12 2000-07-12
US60/217,589 2000-07-12
US09/899,807 2001-07-05
US09/899,807 US20020106348A1 (en) 2000-07-12 2001-07-05 Cancer therapeutics involving the administration of 2-methoxyestradiol and an agent that increases intracellular superoxide anion
PCT/US2001/022332 WO2002003979A2 (en) 2000-07-12 2001-07-11 Combination of 2-methoxyestradiol and an agent that increases intracellular superoxide anion

Publications (1)

Publication Number Publication Date
AU2001273499A1 true AU2001273499A1 (en) 2002-01-21

Family

ID=26912066

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001273499A Abandoned AU2001273499A1 (en) 2000-07-12 2001-07-11 Combination of 2-methoxyestradiol and an agent that increases intracellular superoxide anion

Country Status (3)

Country Link
US (1) US20020106348A1 (en)
AU (1) AU2001273499A1 (en)
WO (1) WO2002003979A2 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7062354B2 (en) 2000-11-08 2006-06-13 Orbotech Ltd. Multi-layer printed circuit board fabrication system and method
CA2790034A1 (en) 2001-06-21 2003-01-03 Isis Pharmaceuticals, Inc. Antisense modulation of superoxide dismutase 1, soluble expression
US20050019915A1 (en) 2001-06-21 2005-01-27 Bennett C. Frank Antisense modulation of superoxide dismutase 1, soluble expression
BRPI0307077A2 (en) * 2002-01-22 2017-06-20 Biomatera Inc method for drying biodegradable polymers
CA2524064A1 (en) * 2003-04-29 2004-11-11 University Of Utah Research Foundation Method for detection and characterization of pre-malignant transformation
WO2005000341A1 (en) * 2003-06-25 2005-01-06 Vib Vzw Use of cytosolic phospholipid hydroperoxide glutathione peroxidase to reduce tumor growth
JP2008501724A (en) * 2004-06-11 2008-01-24 ヴィクトリアン ティッシュ エンジニアリング センター プロプライアトリー リミテッド Tissue material and matrix
US20070148154A1 (en) * 2004-12-17 2007-06-28 Universite Rene Descartes (Paris V) Use of superoxide dismutase mimetics and reductase gultatione in the form of anticancer drugs
ES2304276B1 (en) * 2005-12-23 2009-07-28 Universidad Autonoma De Madrid Uam SYNERGIC EFFECT BETWEEN A CYANOGENIC SYSTEM AND ANOTHER OXIDATIVE INDUCTOR FOR TUMOR TREATMENT.
US8372810B2 (en) * 2007-04-11 2013-02-12 Gene Signal International Sa Anti-tumor drug, medicament, composition, and use thereof
US10485780B2 (en) * 2011-03-14 2019-11-26 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the treatment of proliferative disorders
US9730941B2 (en) 2012-06-07 2017-08-15 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the inhibition of Pin1
SG11201608109TA (en) 2014-04-01 2016-10-28 Ionis Pharmaceuticals Inc Compositions for modulating sod-1 expression
US10351914B2 (en) 2014-07-17 2019-07-16 Beth Israel Deaconess Medical Center, Inc. Biomarkers for Pin1-associated disorders
WO2016011268A1 (en) 2014-07-17 2016-01-21 Beth Israel Deaconess Medical Center, Inc. Atra for modulating pin1 activity and stability
US10548864B2 (en) 2015-03-12 2020-02-04 Beth Israel Deaconess Medical Center, Inc. Enhanced ATRA-related compounds for the treatment of proliferative diseases, autoimmune diseases, and addiction conditions
CN107412161A (en) * 2017-05-22 2017-12-01 河南科技大学 A kind of methoxyestradiol intravenous injection of self-emulsifying 2 and preparation method thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843459A (en) * 1996-01-19 1998-12-01 Human Gene Therapy Research Institute Differential inactivation of nucleic acids by chemical modification
AU765386B2 (en) * 1998-06-10 2003-09-18 Sterix Limited Pharmaceutical composition with tumor necrosis factor a and 2-methoxyestrone-3-(o)-sulphamate for inhibition of estrone sulphatase
IL145995A0 (en) * 1999-04-30 2002-07-25 Sterix Ltd Use
GB9913536D0 (en) * 1999-06-10 1999-08-11 Sterix Ltd Use
US6420378B1 (en) * 1999-10-15 2002-07-16 Supergen, Inc. Inhibition of abnormal cell proliferation with camptothecin and combinations including the same

Also Published As

Publication number Publication date
WO2002003979A2 (en) 2002-01-17
US20020106348A1 (en) 2002-08-08
WO2002003979A3 (en) 2003-07-24

Similar Documents

Publication Publication Date Title
AU2001273499A1 (en) Combination of 2-methoxyestradiol and an agent that increases intracellular superoxide anion
HUP0202302A2 (en) Foaming ingredient and powders containing it
AU3233400A (en) Fire suppression composition and device
AU2001285020A1 (en) P97-active agent conjugates and their methods of use
HUP0301269A3 (en) Phthalazinone derivatives and pharmaceutical compositions containing them
AU5241199A (en) Pharmaceutically acceptable composition comprising an aqueous solution of paclitaxel and albumin
AU1387400A (en) Verification of software agents and agent activities
ZA200402458B (en) Estrogen/gestagen combination preparation and application thereof
AU2001241729A1 (en) Protected forms of pharmacologically active agents and uses therefor
AU2002215300A1 (en) Cancer chemotherapeutical and chemopreventive agent
AU2001273074A1 (en) Combinations of ssri and estrogenic agents
AU2001245783A1 (en) Packaging cushion and packaging assemblies incorporating same
AU4843500A (en) Destructible surfactants and uses thereof
AU2001292047A1 (en) Composition containing an azaphthalocyanine and use
AU2001229439A1 (en) Bioconjugates and uses thereof
AU2742799A (en) Voacamine as anti-malarial agent and anti-malarial agent containing voacamine
AU2002234165A1 (en) Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents
AU2001259441A1 (en) Cellular regulators of infectious agents and methods of use
HUP0303137A3 (en) Bifunctional agents possessing antioxidant and antiarrhythmic activity
AU2002359728A1 (en) Waterproof fragrance releasing device and products incorporating same
AU2002241628A1 (en) Cobalt-porphyrin complexes and use thereof as an anti-obesity agent
AU2002222073A1 (en) Composition containing 7-hydroxy dhea and/or 7-keto dhea and at least an antimicrobial agent
EP1468113A4 (en) Optineurin and glaucoma
AU3666600A (en) Combined x-ray and laser projection device
AU2001235364A1 (en) Tetrahydronaphtalene derivatives and their use